Neurocrine Biosciences Inc vs Eli Lilly & Co.
NBIX vs LLY — side-by-side comparison from reported financials. NBIX leads 3, LLY leads 8 of 11 comparable metrics.
Neurocrine Biosciences Inc
NBIX · Healthcare
$142.44+0.84%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | NBIX | LLY |
|---|---|---|
| Price | $142.44 | $1 177.20 |
| Market cap | $14.5B | $1.05T |
| Revenue (TTM) | $3.37B | $79.7B |
| Revenue growth | +24.3% | +31.7% |
| Net margin | 20.9% | 33.5% |
| Free cash flow | $866M | $18.2B |
| Net cash (debt) | $1.01B | ($35.2B) |
| 1-year price return | +2.9% | +37.6% |
| P/E | 20.5 | 41.6 |
| P/E vs own history (cheap-side %) | 90% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 21% | 93% |
| Altman Z-score | 6.23 | 7.10 |
| CV checks passed | 10 of 10 | 11 of 10 |
| Employees | 2,500 | 50,000 |
Full résumé-style profiles: NBIX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.